Compare Five9 Inc (FIVN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Eli Lilly And Co — how do they compare? Five9 Inc trades at $24.84 (market cap $1.90B), while Eli Lilly And Co trades at $1,179.26 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 542.1× Five9 Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | LLY | |
|---|---|---|
Market Cap | $1.90B | $1.03T |
Sector | Technology | Health |
52-Week High | $29.16 | $1.24K |
52-Week Low | $13.61 | $625.65 |
Enterprise Value | $1.98B | $1.07T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.58, down 0.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $27.00. The company has shown consistent revenue growth, reaching $1.15 billion in 2025, and has beaten earnings estimates for the last three quarters. Recent news highlights include new executive appointments and AI product launches, though some legal scrutiny regarding fiduciary duties exists.
The outlook is positive given strong earnings beats and revenue growth, but risks include high valuation multiples, negative net cash flow, and ongoing legal investigations. Analyst sentiment remains largely bullish, supporting potential upside to the price target.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
